ARCT 154
Alternative Names: ARCT-154; Kostaive; VBC-COV19-154Latest Information Update: 06 Oct 2025
At a glance
- Originator Arcturus Therapeutics
- Developer Arcturus Therapeutics; Meiji Seika Pharma; Vinbiocare Biotechnology
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 30 Sep 2025 Pharmacodynamics data from a preclinical trials in COVID 2019 infections released by Arcturus Therapeutics
- 26 Sep 2025 Meiji Seika Pharma launch 2-dose lyophilized presentation of KOSTAIVE® in Japan (IM, Injection)
- 28 Aug 2025 Meiji Seika Pharma received manufacturing and marketing approval in Japan for a 2-dose lyophilized presentation of KOSTAIVE®